Michael Alexander Smith Sells 1,806 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 1,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total transaction of $173,050.92. Following the transaction, the insider directly owned 37,648 shares of the company’s stock, valued at $3,607,431.36. This represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Alexander Smith also recently made the following trade(s):

• On Wednesday, June 3rd, Michael Alexander Smith sold 2,159 shares of Insmed stock. The shares were sold at an average price of $102.27, for a total value of $220,800.93.
• On Friday, May 22nd, Michael Alexander Smith sold 6,149 shares of Insmed stock. The shares were sold at an average price of $108.47, for a total value of $666,982.03.
• On Monday, March 30th, Michael Alexander Smith sold 19,638 shares of Insmed stock. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24.

Insmed Stock Up 1.0%

INSM opened at $104.47 on Friday. The firm has a market capitalization of $22.64 billion, a P/E ratio of -18.17 and a beta of 0.79. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The company has a fifty day moving average price of $113.76 and a 200-day moving average price of $144.11. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. Insmed’s revenue for the quarter was up 229.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.42) earnings per share. Equities research analysts expect that Insmed, Inc. will post -2.55 earnings per share for the current fiscal year.

Institutional Trading of Insmed

A number of institutional investors have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC increased its stake in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. CoreCap Advisors LLC purchased a new stake in Insmed during the 4th quarter valued at $27,000. GraniteShares Advisors LLC purchased a new stake in Insmed during the 4th quarter valued at $30,000. Reflection Asset Management bought a new stake in Insmed in the 4th quarter worth $30,000. Finally, Raiffeisen Bank International AG bought a new stake in Insmed in the 4th quarter worth $32,000.

Wall Street Analyst Weigh In

INSM has been the topic of a number of recent research reports. Guggenheim reduced their price target on shares of Insmed from $230.00 to $226.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Bank of America upped their price objective on shares of Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Barclays lifted their target price on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Finally, Royal Bank Of Canada lowered their price target on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $211.86.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.